Testosterone challenge and androgen receptor activity in relation to UGT2B17 genotypes

We investigated the androgen receptor (AR) bioluminescense response in serum and urine before and after testosterone challenge in different genotypes of the UGT2B17 enzyme, which catalyses testosterone glucuronidation.

[1]  J. Schulze,et al.  Androgen sulfation in healthy UDP-glucuronosyl transferase 2B17 enzyme-deficient men. , 2011, The Journal of clinical endocrinology and metabolism.

[2]  J. Schulze,et al.  Bioavailability of testosterone enanthate dependent on genetic variation in the phosphodiesterase 7B but not on the uridine 5′-diphospho-glucuronosyltransferase (UGT2B17) gene. , 2011, Pharmacogenetics and genomics.

[3]  Elisa Michelini,et al.  Analytical strategies for improving the robustness and reproducibility of bioluminescent microbial bioreporters , 2011, Analytical and bioanalytical chemistry.

[4]  Elisa Michelini,et al.  A portable bioluminescence engineered cell-based biosensor for on-site applications. , 2011, Biosensors & bioelectronics.

[5]  M. Parr,et al.  Long-term detection of methyltestosterone (ab-) use by a yeast transactivation system , 2011, Archives of Toxicology.

[6]  G. Rödel,et al.  A novel combined approach to detect androgenic activities with yeast based assays in Schizosaccharomyces pombe and Saccharomyces cerevisiae. , 2010, Toxicology letters.

[7]  A. Petróczi,et al.  Potentially harmful advantage to athletes: a putative connection between UGT2B17 gene deletion polymorphism and renal disorders with prolonged use of anabolic androgenic steroids , 2010, Substance abuse treatment, prevention, and policy.

[8]  Saskia S Sterk,et al.  Detection of anabolic androgenic steroid abuse in doping control using mammalian reporter gene bioassays. , 2009, Analytica chimica acta.

[9]  Christof Van Poucke,et al.  Detection of anabolic steroids in dietary supplements: the added value of an androgen yeast bioassay in parallel with a liquid chromatography-tandem mass spectrometry screening method. , 2009, Analytica chimica acta.

[10]  J. Schulze,et al.  Substantial advantage of a combined Bayesian and genotyping approach in testosterone doping tests , 2009, Steroids.

[11]  M. Karp,et al.  A sensitive recombinant cell-based bioluminescent assay for detection of androgen-like compounds , 2008, Nature Protocols.

[12]  G. Vollmer,et al.  Detection of anabolic steroid abuse using a yeast transactivation system , 2008, Steroids.

[13]  J. Schulze,et al.  Doping test results dependent on genotype of uridine diphospho-glucuronosyl transferase 2B17, the major enzyme for testosterone glucuronidation. , 2008, The Journal of clinical endocrinology and metabolism.

[14]  T. Fears,et al.  Reproducibility of Serum Sex Steroid Assays in Men by RIA and Mass Spectrometry , 2007, Cancer Epidemiology Biomarkers & Prevention.

[15]  R. Bérubé,et al.  Metabolism of DHEA in postmenopausal women following percutaneous administration , 2007, The Journal of Steroid Biochemistry and Molecular Biology.

[16]  Claes Ohlsson,et al.  Large differences in testosterone excretion in Korean and Swedish men are strongly associated with a UDP-glucuronosyl transferase 2B17 polymorphism. , 2006, The Journal of clinical endocrinology and metabolism.

[17]  A. Matsumoto,et al.  Long-term administration of testosterone enanthate to normal men: Alterations of the urinary profile of androgen metabolites potentially useful for detection of testosterone misuse in sport , 1993, The Journal of Steroid Biochemistry and Molecular Biology.

[18]  J. Stanghelle,et al.  Detection of testosterone administration by increased ratio between serum concentrations of testosterone and 17 alpha-hydroxyprogesterone. , 1992, Clinical chemistry.